Publication | Closed Access

Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study

Diabetes ManagementCardiovascular DiseaseMedicineInsulin ManagementDiabetesCardiovascular RiskType 2PharmacotherapyDiabetes MellitusPharmacologyProton Pump InhibitorAnesthesiology